Prime Time for Proteomics in Pulmonary Arterial Hypertension Risk Assessment?
Am J Respir Crit Care Med
.
2022 May 1;205(9):988-990.
doi: 10.1164/rccm.202201-0040ED.
Authors
Navneet Singh
1
,
Corey E Ventetuolo
2
3
Affiliations
1
Division of Pulmonary, Critical Care and Sleep Medicine Brown University Providence, Rhode Island.
2
Division of Pulmonary, Critical Care and Sleep Medicine.
3
Department of Health Services, Policy and Practice Brown University Providence, Rhode Island.
PMID:
35143371
PMCID:
PMC9851471
DOI:
10.1164/rccm.202201-0040ED
No abstract available
Publication types
Editorial
Research Support, N.I.H., Extramural
Comment
MeSH terms
Familial Primary Pulmonary Hypertension
Humans
Proteome
Proteomics
Pulmonary Arterial Hypertension* / diagnosis
Risk Assessment
Substances
Proteome
Grants and funding
R01 HL141268/HL/NHLBI NIH HHS/United States